We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes (ALKS) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Alkermes (ALKS - Free Report) closed at $24.51, marking a +0.62% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.07%. Meanwhile, the Dow lost 1.07%, and the Nasdaq, a tech-heavy index, lost 0.07%.
Coming into today, shares of the drugmaker had lost 5.95% in the past month. In that same time, the Medical sector lost 4.02%, while the S&P 500 lost 3.49%.
Wall Street will be looking for positivity from Alkermes as it approaches its next earnings report date. On that day, Alkermes is projected to report earnings of $0.02 per share, which would represent a year-over-year decline of 85.71%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $274.33 million, down 6.73% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.20 per share and revenue of $1.11 billion. These totals would mark changes of -74.36% and -5.72%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Alkermes. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 3% higher. Alkermes currently has a Zacks Rank of #3 (Hold).
Investors should also note Alkermes's current valuation metrics, including its Forward P/E ratio of 121.8. Its industry sports an average Forward P/E of 20.5, so we one might conclude that Alkermes is trading at a premium comparatively.
We can also see that ALKS currently has a PEG ratio of 4.89. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ALKS's industry had an average PEG ratio of 1.36 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 59, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alkermes (ALKS) Gains As Market Dips: What You Should Know
In the latest trading session, Alkermes (ALKS - Free Report) closed at $24.51, marking a +0.62% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.07%. Meanwhile, the Dow lost 1.07%, and the Nasdaq, a tech-heavy index, lost 0.07%.
Coming into today, shares of the drugmaker had lost 5.95% in the past month. In that same time, the Medical sector lost 4.02%, while the S&P 500 lost 3.49%.
Wall Street will be looking for positivity from Alkermes as it approaches its next earnings report date. On that day, Alkermes is projected to report earnings of $0.02 per share, which would represent a year-over-year decline of 85.71%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $274.33 million, down 6.73% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $0.20 per share and revenue of $1.11 billion. These totals would mark changes of -74.36% and -5.72%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Alkermes. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 3% higher. Alkermes currently has a Zacks Rank of #3 (Hold).
Investors should also note Alkermes's current valuation metrics, including its Forward P/E ratio of 121.8. Its industry sports an average Forward P/E of 20.5, so we one might conclude that Alkermes is trading at a premium comparatively.
We can also see that ALKS currently has a PEG ratio of 4.89. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ALKS's industry had an average PEG ratio of 1.36 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 59, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.